



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022 .

Rs. In Lakhs

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		Un-Audited	Refer note.7	Un-Audited	Audited
1	Income	(1)	(2)	(3)	(4)
	Revenue from operations	353.92	422.13	200.61	1,184.43
	Other Income	43.58	11.81	83.95	160.14
	Total income	397.50	433.94	284.56	1,344.57
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	415.87	505.67	409.74	1,746.40
	d) Finance costs	10.17	9.78	15.29	53.01
	e) Depreciation and amortisation expense	158.11	110.23	103.43	439.32
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	502.45	402.53	884.01	2,453.42
	h) Other Expenses	142.14	261.10	92.95	648.85
	Total expenses	1,228.74	1,289.31	1,505.42	5,341.00
3	Profit before exceptional items & Tax (1-2)	(831.24)	(855.37)	(1,220.86)	(3,996.43)
4	Exceptional Items- (Ref Note:6)	600.00	-	371.57	371.57
5	Profit before Tax (3-4)	(231.24)	(855.37)	(849.29)	(3,624.86)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(231.24)	(855.37)	(849.29)	(3,624.86)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(3.76)	20.31	(11.79)	(15.05)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(3.76)	20.31	(11.79)	(15.05)
9	Total Comprehensive Income for the period (7+8)	(235.00)	(835.06)	(861.08)	(3,639.91)
10	Paid-up equity share capital	1,453.82	1,453.82	1,272.82	1,453.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	46,143.89
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(0.16)	(0.67)	(0.67)	(2.84)
	b) Diluted	(0.16)	(0.67)	(0.67)	(2.84)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



Rs. In Lakhs					
PART - I		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		Un-Audited	Refer note.7	Un-Audited	Audited
1	Income	(1)	(2)	(3)	(4)
	Revenue from operations	353.92	422.13	200.61	1,184.43
	Other Income	43.58	11.82	83.95	160.14
	Total income	397.50	433.95	284.56	1,344.57
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	485.13	576.19	505.53	2,102.08
	d) Finance costs	10.17	9.78	15.29	53.01
	e) Depreciation and amortisation expense	158.11	110.23	103.43	439.32
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	1,824.96	1,545.75	3,852.23	10,636.75
	h) Other Expenses	151.75	271.81	100.50	684.49
	Total expenses	2,630.12	2,513.76	4,576.98	13,915.65
3	Profit before exceptional items, Tax (1-2)	(2,232.62)	(2,079.81)	(4,292.42)	(12,571.08)
4	Exceptional Items- (Ref Note:6)	600.00	-	371.57	371.57
5	Profit before Tax (3-4)	(1,632.62)	(2,079.81)	(3,920.85)	(12,199.51)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(1,632.62)	(2,079.81)	(3,920.85)	(12,199.51)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(3.76)	20.31	(11.79)	(15.05)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(3.76)	20.31	(11.79)	(15.05)
9	Total Comprehensive Income for the period (7+ 8)	(1,636.38)	(2,059.50)	(3,932.64)	(12,214.56)
10	Paid-up equity share capital Face Value of the Share	1,453.82 Re.1.00	1,453.82 Re.1.00	1,272.82 Re.1.00	1,453.82 Re.1.00
11	Other Equity	-	-	-	8,160.71
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(1.12)	(1.63)	(3.08)	(9.57)
	b) Diluted	(1.12)	(1.63)	(3.08)	(9.57)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 26, 2022. The results for the quarter ended June 30, 2022 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The Board of directors of the Company at their meeting held on June 24, 2022 approved raising of funds, through issuance of equity shares having face value of ₹ 1 each up to an aggregate amount of ₹ 400 Crores (Rupees Four Hundred Crores) on rights basis.

6) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant , certain fixed assets and other contents in buildings was damaged. The Company has lodged Insurance claim subsequently during the quarter received an amount of Rs. 600.00 Lakhs and till date an amount of Rs.1200.00 Lakhs from Insurance company, the same has been included in exceptional Item and regrouped for previous year.

7) The figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year.

8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : 26th July'2022



For SUVEN LIFE SCIENCES LTD


VENKAT JASTI

Chairman & CEO

DIN: 00278028